Diet Science is a fun 7 to 8 minute weekly program with insights and straight scoops on today's health and diet issues from Dee McCaffrey, CDC. Dee is an Organic Chemist who lost 100 pounds, nearly half her body weight, and has kept it off for 20 years by staying away from processed foods. She's the author of The Science of Skinny, released by Perseus June 2012, and The Science of Skinny Cookbook, which was released December 2014.
…
continue reading
Content provided by Strokefocus Podcast and Wohaula LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Strokefocus Podcast and Wohaula LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Episode 93 Multistem A Game Changer - Interview With Gil Van Bokkelen, CEO of Athersys
MP3•Episode home
Manage episode 237530767 series 1345252
Content provided by Strokefocus Podcast and Wohaula LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Strokefocus Podcast and Wohaula LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Multistem®, a drug-like cell therapy to treat stroke with adult stem cells is developed by Athersys (ATH-er-sis), a clinical-stage biotechnology company founded by a group of leading scientists in 1995. In Episode 91, we interviewed Sharon Thomas, a survivor who experienced miraculous recovery after given multistem. Athersys is conducting the Phase 3 clinical trials for MultiStem®. During Phase 2 trials in the U.S, the studies showed that MultiStem® could extend the treatment window for ischemic stroke patients to 36 hours, compared to the 3 or 4 hour window to treat patients with TPA. That meant individuals who may have had a stroke in their sleep, or patients who did not recognize the symptoms right away, might still have a favorable outcome with MultiStem® versus TPA. Multistem® has obtained FDA’s Fast Track designation. It is also in Phase 3 studies in Japan. Our guest today is Gil Van Bokkelen, CEO of Athersys, who will share with us exciting progress of Multistem®.
…
continue reading
106 episodes
MP3•Episode home
Manage episode 237530767 series 1345252
Content provided by Strokefocus Podcast and Wohaula LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Strokefocus Podcast and Wohaula LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Multistem®, a drug-like cell therapy to treat stroke with adult stem cells is developed by Athersys (ATH-er-sis), a clinical-stage biotechnology company founded by a group of leading scientists in 1995. In Episode 91, we interviewed Sharon Thomas, a survivor who experienced miraculous recovery after given multistem. Athersys is conducting the Phase 3 clinical trials for MultiStem®. During Phase 2 trials in the U.S, the studies showed that MultiStem® could extend the treatment window for ischemic stroke patients to 36 hours, compared to the 3 or 4 hour window to treat patients with TPA. That meant individuals who may have had a stroke in their sleep, or patients who did not recognize the symptoms right away, might still have a favorable outcome with MultiStem® versus TPA. Multistem® has obtained FDA’s Fast Track designation. It is also in Phase 3 studies in Japan. Our guest today is Gil Van Bokkelen, CEO of Athersys, who will share with us exciting progress of Multistem®.
…
continue reading
106 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.